PAVS
Paranovus Entertainment Technology Ltd.
Packaged Foods
Market Cap$69K
5Y Perf.-100.0%
Compare Stocks
5 / 10Try these comparisons:
Stock Comparison
PAVS vs XTLB vs NRXP vs TAOP vs AEYE
Revenue, margins, valuation, and 5-year total return — side by side.
XTLB
XTL Biopharmaceuticals Ltd.
Biotechnology
Market Cap$279K
5Y Perf.-52.6%
NRXP
NRx Pharmaceuticals, Inc.
Biotechnology
Market Cap$85M
5Y Perf.-97.2%
TAOP
Taoping Inc.
Software - Infrastructure
Market Cap$1M
5Y Perf.-99.8%
AEYE
AudioEye, Inc.
Software - Application
Market Cap$98M
5Y Perf.-7.2%
PAVS vs XTLB vs NRXP vs TAOP vs AEYE — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | PAVS | XTLB | NRXP | TAOP | AEYE |
|---|---|---|---|---|---|
| Industry | Packaged Foods | Biotechnology | Biotechnology | Software - Infrastructure | Software - Application |
| Market Cap | $69K | $279K | $85M | $1M | $98M |
| Revenue (TTM) | $13M | $451K | $242K | $36M | $40M |
| Net Income (TTM) | $-27M | $-1M | $-38M | $-7M | $-3M |
| Gross Margin | 11.1% | 26.4% | 59.5% | 14.9% | 78.3% |
| Operating Margin | -10.3% | -481.6% | -63.0% | -15.7% | -7.9% |
| Forward P/E | 0.0x | — | — | — | — |
| Total Debt | $2M | $138K | $631K | $10M | $721K |
| Cash & Equiv. | $261K | $371K | $8M | $2M | $5M |
PAVS vs XTLB vs NRXP vs TAOP vs AEYE — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
PAVS
XTLB
NRXP
TAOP
AEYE
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Paranovus Entertain… (PAVS) | 100 | 0.0 | -100.0% |
| XTL Biopharmaceutic… (XTLB) | 100 | 47.4 | -52.6% |
| NRx Pharmaceuticals… (NRXP) | 100 | 2.8 | -97.2% |
| Taoping Inc. (TAOP) | 100 | 0.2 | -99.8% |
| AudioEye, Inc. (AEYE) | 100 | 92.8 | -7.2% |
Price return only. Dividends and distributions are not included.
Quick Verdict: PAVS vs XTLB vs NRXP vs TAOP vs AEYE
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: NRXP and AEYE are tied at the top with 2 categories each (5-stock set) — the right choice depends on your priorities. AudioEye, Inc. is the stronger pick specifically for profitability and margin quality and operational efficiency and capital deployment. PAVS also leads in specific categories worth noting. This set spans 3 sectors — these stocks serve different portfolio roles, not just different price points.
PAVS
Paranovus Entertainment Technology Ltd.
The Income Pick
PAVS ranks third and is worth considering specifically for income & stability and sleep-well-at-night.
- Dividend streak 0 yrs, beta 1.53
- Lower volatility, beta 1.53, Low D/E 8.1%, current ratio 1.12x
- Beta 1.53, current ratio 1.12x
- Beta 1.53 vs TAOP's 2.26, lower leverage
Best for: income & stability and sleep-well-at-night
XTLB
XTL Biopharmaceuticals Ltd.
The Healthcare Pick
XTLB lags the leaders in this set but could rank higher in a more targeted comparison.
Best for: healthcare exposure
NRXP
NRx Pharmaceuticals, Inc.
The Growth Leader
NRXP carries the broadest edge in this set and is the clearest fit for growth and momentum.
- 101.1% revenue growth vs XTLB's -173.2%
- +50.2% vs PAVS's -99.9%
Best for: growth and momentum
TAOP
Taoping Inc.
The Technology Pick
Among these 5 stocks, TAOP doesn't own a clear edge in any measured category.
Best for: technology exposure
AEYE
AudioEye, Inc.
The Growth Play
AEYE is the #2 pick in this set and the best alternative if growth exposure and long-term compounding is your priority.
- Rev growth 14.5%, EPS growth 30.6%, 3Y rev CAGR 10.5%
- 96.5% 10Y total return vs XTLB's -87.9%
- -7.6% margin vs NRXP's -157.3%
- -9.5% ROA vs NRXP's -489.9%
Best for: growth exposure and long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | NRXP | 101.1% revenue growth vs XTLB's -173.2% |
| Quality / Margins | AEYE | -7.6% margin vs NRXP's -157.3% |
| Stability / Safety | PAVS | Beta 1.53 vs TAOP's 2.26, lower leverage |
| Dividends | Tie | None of these 5 stocks pay a meaningful dividend |
| Momentum (1Y) | NRXP | +50.2% vs PAVS's -99.9% |
| Efficiency (ROA) | AEYE | -9.5% ROA vs NRXP's -489.9% |
PAVS vs XTLB vs NRXP vs TAOP vs AEYE — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
Segment breakdown not available.
FY 2025
FY 2025
FY 2024
PAVS vs XTLB vs NRXP vs TAOP vs AEYE — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLAEYELAGGINGTAOP
Who Leads Where
AEYE leads in 2 of 6 categories
PAVS leads 0 • XTLB leads 0 • NRXP leads 0 • TAOP leads 0 • 4 tied
Explore the data ↓TAOPTaoping Inc.
0leads
NRXPNRx Pharmaceuticals, …
0leads
XTLBXTL Biopharmaceutical…
0leads
PAVSParanovus Entertainme…
0leads
AEYEAudioEye, Inc.
2leads
6 Total Categories
CATEGORYLEADERvs PAVSvs XTLBMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
AEYE4/6
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
Tied
—
Total Returns1Y, 3Y, 5Y total returns with dividends
AEYE4/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
Tied
—
Income & Cash Flow (Last 12 Months)
AEYE leads this category, winning 4 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
AEYE is the larger business by revenue, generating $40M annually — 166.6x NRXP's $242,000. AEYE is the more profitable business, keeping -7.6% of every revenue dollar as net income compared to NRXP's -157.3%. On growth, PAVS holds the edge at +180.3% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | PAVSParanovus Enterta… | XTLBXTL Biopharmaceut… | NRXPNRx Pharmaceutica… | TAOPTaoping Inc. | AEYEAudioEye, Inc. |
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $13M | $451,000 | $242,000 | $36M | $40M |
| EBITDAEarnings before interest/tax | $531,773 | -$1M | -$31M | -$4M | -$504,000 |
| Net IncomeAfter-tax profit | -$27M | -$1M | -$38M | -$7M | -$3M |
| Free Cash FlowCash after capex | -$3M | $0 | -$12M | -$3M | $2M |
| Gross MarginGross profit ÷ Revenue | +11.1% | +26.4% | +59.5% | +14.9% | +78.3% |
| Operating MarginEBIT ÷ Revenue | -10.3% | -4.8% | -63.0% | -15.7% | -7.9% |
| Net MarginNet income ÷ Revenue | -2.1% | -2.3% | -157.3% | -19.6% | -7.6% |
| FCF MarginFCF ÷ Revenue | -23.5% | -3.7% | -49.0% | -8.1% | +5.5% |
| Rev. Growth (YoY)Latest quarter vs prior year | +180.3% | — | — | -2.6% | +7.9% |
| EPS Growth (YoY)Latest quarter vs prior year | +76.9% | +20.0% | -80.0% | -51.7% | +29.0% |
AEYE leads this category, winning 4 of 6 comparable metrics.
Valuation Metrics
Evenly matched — PAVS and TAOP and AEYE each lead in 1 of 3 comparable metrics.
Valuation Metrics
| Metric | PAVSParanovus Enterta… | XTLBXTL Biopharmaceut… | NRXPNRx Pharmaceutica… | TAOPTaoping Inc. | AEYEAudioEye, Inc. |
|---|---|---|---|---|---|
| Market CapShares × price | $68,949 | $279,464 | $85M | $1M | $98M |
| Enterprise ValueMkt cap + debt − cash | $2M | $46,464 | $78M | $9M | $93M |
| Trailing P/EPrice ÷ TTM EPS | -0.01x | -0.26x | -2.30x | -0.16x | -31.44x |
| Forward P/EPrice ÷ next-FY EPS est. | 0.00x | — | — | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | — | — |
| EV / EBITDAEnterprise value multiple | — | — | — | — | — |
| Price / SalesMarket cap ÷ Revenue | 0.96x | 0.62x | 69.60x | 0.04x | 2.42x |
| Price / BookPrice ÷ Book value/share | 0.00x | 0.05x | — | 0.08x | 20.31x |
| Price / FCFMarket cap ÷ FCF | — | — | — | — | — |
Evenly matched — PAVS and TAOP and AEYE each lead in 1 of 3 comparable metrics.
Profitability & Efficiency
Evenly matched — XTLB and AEYE each lead in 3 of 9 comparable metrics.
Profitability & Efficiency
XTLB delivers a -25.5% return on equity — every $100 of shareholder capital generates $-26 in annual profit, vs $-116 for PAVS. XTLB carries lower financial leverage with a 0.03x debt-to-equity ratio, signaling a more conservative balance sheet compared to TAOP's 0.50x. On the Piotroski fundamental quality scale (0–9), PAVS scores 5/9 vs TAOP's 2/9, reflecting solid financial health.
| Metric | PAVSParanovus Enterta… | XTLBXTL Biopharmaceut… | NRXPNRx Pharmaceutica… | TAOPTaoping Inc. | AEYEAudioEye, Inc. |
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | -116.2% | -25.5% | — | -46.7% | -47.8% |
| ROA (TTM)Return on assets | -94.4% | -17.7% | -4.9% | -21.7% | -9.5% |
| ROICReturn on invested capital | -27.1% | -54.1% | — | -27.1% | -42.4% |
| ROCEReturn on capital employed | -39.5% | -50.7% | — | -38.0% | -17.7% |
| Piotroski ScoreFundamental quality 0–9 | 5 | 3 | 5 | 2 | 4 |
| Debt / EquityFinancial leverage | 0.08x | 0.03x | — | 0.50x | 0.15x |
| Net DebtTotal debt minus cash | $2M | -$233,000 | -$7M | $8M | -$5M |
| Cash & Equiv.Liquid assets | $261,355 | $371,000 | $8M | $2M | $5M |
| Total DebtShort + long-term debt | $2M | $138,000 | $631,000 | $10M | $721,000 |
| Interest CoverageEBIT ÷ Interest expense | -11.83x | -13.31x | -24.18x | -52.63x | -2.79x |
Evenly matched — XTLB and AEYE each lead in 3 of 9 comparable metrics.
Total Returns (Dividends Reinvested)
AEYE leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in AEYE five years ago would be worth $4,233 today (with dividends reinvested), compared to $0 for PAVS. Over the past 12 months, NRXP leads with a +50.2% total return vs PAVS's -99.9%. The 3-year compound annual growth rate (CAGR) favors AEYE at 5.4% vs PAVS's -93.3% — a key indicator of consistent wealth creation.
| Metric | PAVSParanovus Enterta… | XTLBXTL Biopharmaceut… | NRXPNRx Pharmaceutica… | TAOPTaoping Inc. | AEYEAudioEye, Inc. |
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | -94.9% | +5.8% | +17.6% | -7.3% | -21.0% |
| 1-Year ReturnPast 12 months | -99.9% | -52.3% | +50.2% | -78.7% | -34.1% |
| 3-Year ReturnCumulative with dividends | -100.0% | -48.4% | -50.3% | -99.3% | +17.1% |
| 5-Year ReturnCumulative with dividends | -100.0% | -81.5% | -99.0% | -99.9% | -57.7% |
| 10-Year ReturnCumulative with dividends | -100.0% | -87.9% | -96.8% | -99.9% | +96.5% |
| CAGR (3Y)Annualised 3-year return | -93.3% | -19.8% | -20.8% | -80.9% | +5.4% |
AEYE leads this category, winning 4 of 6 comparable metrics.
Risk & Volatility
Evenly matched — PAVS and NRXP each lead in 1 of 2 comparable metrics.
Risk & Volatility
PAVS is the less volatile stock with a 1.53 beta — it tends to amplify market swings less than TAOP's 2.26 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. NRXP currently trades 80.2% from its 52-week high vs PAVS's 0.1% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | PAVSParanovus Enterta… | XTLBXTL Biopharmaceut… | NRXPNRx Pharmaceutica… | TAOPTaoping Inc. | AEYEAudioEye, Inc. |
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.53x | 1.64x | 1.89x | 2.26x | 2.18x |
| 52-Week HighHighest price in past year | $1488.00 | $10.28 | $3.84 | $20.10 | $16.39 |
| 52-Week LowLowest price in past year | $1.02 | $1.05 | $1.62 | $1.18 | $5.31 |
| % of 52W HighCurrent price vs 52-week peak | +0.1% | +24.7% | +80.2% | +6.4% | +48.0% |
| RSI (14)Momentum oscillator 0–100 | 32.5 | 46.2 | 65.0 | 49.4 | 66.5 |
| Avg Volume (50D)Average daily shares traded | 1.3M | 2.4M | 924K | 20K | 195K |
Evenly matched — PAVS and NRXP each lead in 1 of 2 comparable metrics.
Analyst Outlook
Evenly matched — TAOP and AEYE each lead in 1 of 1 comparable metric.
Analyst Outlook
| Metric | PAVSParanovus Enterta… | XTLBXTL Biopharmaceut… | NRXPNRx Pharmaceutica… | TAOPTaoping Inc. | AEYEAudioEye, Inc. |
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | — | — | — | — |
| Price TargetConsensus 12-month target | — | — | — | — | — |
| # AnalystsCovering analysts | — | — | — | — | — |
| Dividend YieldAnnual dividend ÷ price | — | — | — | — | — |
| Dividend StreakConsecutive years of raises | 0 | — | — | 1 | 1 |
| Dividend / ShareAnnual DPS | — | — | — | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Evenly matched — TAOP and AEYE each lead in 1 of 1 comparable metric.
Key Takeaway
AEYE leads in 2 of 6 categories — strongest in Income & Cash Flow and Total Returns. 4 categories are tied.
Best OverallAudioEye, Inc. (AEYE)Leads 2 of 6 categories
Loading custom metrics...
PAVS vs XTLB vs NRXP vs TAOP vs AEYE: Key Questions Answered
8 questions · data-driven answers · updated daily
01Is PAVS or XTLB or NRXP or TAOP or AEYE a better buy right now?
For growth investors, AudioEye, Inc.
(AEYE) is the stronger pick with 14. 5% revenue growth year-over-year, versus -98. 9% for Paranovus Entertainment Technology Ltd. (PAVS). The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — PAVS or XTLB or NRXP or TAOP or AEYE?
Over the past 5 years, AudioEye, Inc.
(AEYE) delivered a total return of -57. 7%, compared to -100. 0% for Paranovus Entertainment Technology Ltd. (PAVS). Over 10 years, the gap is even starker: AEYE returned +96. 5% versus PAVS's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — PAVS or XTLB or NRXP or TAOP or AEYE?
By beta (market sensitivity over 5 years), Paranovus Entertainment Technology Ltd.
(PAVS) is the lower-risk stock at 1. 53β versus Taoping Inc. 's 2. 26β — meaning TAOP is approximately 48% more volatile than PAVS relative to the S&P 500. On balance sheet safety, XTL Biopharmaceuticals Ltd. (XTLB) carries a lower debt/equity ratio of 3% versus 50% for Taoping Inc. — giving it more financial flexibility in a downturn.
04Which is growing faster — PAVS or XTLB or NRXP or TAOP or AEYE?
By revenue growth (latest reported year), AudioEye, Inc.
(AEYE) is pulling ahead at 14. 5% versus -98. 9% for Paranovus Entertainment Technology Ltd. (PAVS). On earnings-per-share growth, the picture is similar: Paranovus Entertainment Technology Ltd. grew EPS 96. 4% year-over-year, compared to -1870. 0% for Taoping Inc.. Over a 3-year CAGR, AEYE leads at 10. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — PAVS or XTLB or NRXP or TAOP or AEYE?
AudioEye, Inc.
(AEYE) is the more profitable company, earning -7. 6% net margin versus -110. 3% for Paranovus Entertainment Technology Ltd. — meaning it keeps -7. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: AEYE leads at -7. 9% versus -94. 8% for PAVS. At the gross margin level — before operating expenses — AEYE leads at 78. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — PAVS or XTLB or NRXP or TAOP or AEYE?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is PAVS or XTLB or NRXP or TAOP or AEYE better for a retirement portfolio?
For long-horizon retirement investors, Paranovus Entertainment Technology Ltd.
(PAVS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding. Taoping Inc. (TAOP) carries a higher beta of 2. 26 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (PAVS: -100. 0%, TAOP: -99. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between PAVS and XTLB and NRXP and TAOP and AEYE?
These companies operate in different sectors (PAVS (Consumer Defensive) and XTLB (Healthcare) and NRXP (Healthcare) and TAOP (Technology) and AEYE (Technology)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.